Dr Dev Samarasinghe

Clinical Senior Lecturer
Medicine, Westmead Clinical School

Telephone +61 2 9845 7499
Fax +61 2 9635 7582

Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Nguyen, V., Tan, P., Greenup, A., Glass, A., Davison, S., Samarasinghe, D., Holdaway, S., Strasser, S., Chatterjee, U., Jackson, K., et al (2014). Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Alimentary Pharmacology and Therapeutics, 39(10), 1225-1234. [More Information]
  • Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. American Journal of Gastroenterology, 99(4), 636-644.
  • Sud, A., Hui, J., Farrell, G., Bandara, P., Kench, J., Fung, C., Lin, R., Samarasinghe, D., Liddle, C., McCaughan, G., George, J. (2004). Improved Prediction Of Fibrosis In Chronic Hepatitis C Using Measures Of Insulin Resistance In A Probability Index. Hepatology, 39(5), 1239-1247. [More Information]
  • Coverdale, S., Samarasinghe, D., Lin, R., Kench, J., Byth Wilson, K., Khan, M., Crewe, E., Liddle, C., George, J., Farrell, G. (2003). Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression. American Journal of Gastroenterology, 98(6), 1384-1390.
  • Kumar, D., Wallington-Beddoe, C., George, J., Lin, R., Samarasinghe, D., Liddle, C., Farrell, G. (2003). Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hapatitis c in a clinic setting. Medical Journal of Australia, 178(6), 267-271.
  • Hui, J., George, J., Liddle, C., Lin, R., Samarasinghe, D., Crewe, E., Farrell, G. (2002). Changes in Serum Albumin During Treatment of Chronic Hepatitis B With Lamivudine: Effects of Response and Emergence of Drug Resistance. American Journal of Gastroenterology, 97(4), 1003-1009.
  • Hui, J., Kench, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., Byth, K., George, J. (2002). Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., George, J., Kench, J., Byth, K. (2002). Hepatic Steatosis in Chronic Hepatitis C Infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Chitturi, S., Weltman, M., Farrell, G., McDonald, D., Liddle, C., Samarasinghe, D., Lin, R., Abeygunasekera, S., George, J. (2002). HFE Mutations, Hepatic Iron, and Fibrosis: Ethnic-Specification Association of NASH with C282Y but not with Fibrotic Severity. Hepatology, 36(1), 142-149.
  • Chitturi, S., Abeygunasekera, S., Farrell, G., Holmes-Walker, J., Hui, J., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J. (2002). NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology, 35(2), 373-379.
  • Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., George, J. (2002). Serum Leptin in NASH Correlates with Hepatic Steatosis but not Fibrosis: A Manifestation of Lipotoxicity? Hepatology, 36(2), 403-409.
  • Chitturi, S., Abeygunasekera, S., Fung, C., Samarasinghe, D., Lin, R., McDonald, D., Weltman, M., Farrell, G., George, J. (2001). Haemochromatosis gene mutations, hepatic iron content and nonalcoholic steatohepatitis. Hepatology, 19, 1768-1778.
  • Farrell, G., Samarasinghe, D., Chitturi, S., Abeygunasekera, S., Fung, C. (2001). HFE mutations, hepatic iron content and nonalcoholic steatohepatitis. Journal of Gastroenterology and Hepatology, 16.
  • George, J., Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Kench, J. (2001). Predictors for steatosis and fibrosis in chronic hepatitis C. Journal of Hepatology, 34, 153-153.
  • Farrell, G., Liddle, C., Samarasinghe, D., Chitturi, S., Frost, L. (2001). Serum leptin is a predictor of severity of hepatic steatosis in NASH but does not correlate with fibrotic severity. Journal of Gastroenterology and Hepatology, 16.
  • Farrell, G., Liddle, C., Samarasinghe, D., Lin, R., George, J., Chitturi, S., Frost, L. (2001). Serum Leptin: An independent predictor of hepatic steatosis but not fibrotic severity in nonalcoholic steatohepatitis. Hepatology, 34, 752-752.

Conferences

  • Coverdale, S., Samarasinghe, D., Lin, R., Liddle, C., George, J., Farrell, G., Kench, J., Byth, K., Khan, M., Crewe, E. (2001). Prediction of histological progression in chronic hepatitis C. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Farrell, G., Liddle, C., Samarasinghe, D., Chitturi, S., Frost, L. (2001). Serum is a predictor of severity of hepatic steatosis in NASH but does not correlate with fibrotic severity. Asia Pacific Digestive Week 2001, : World Scientific Publishing.

2014

  • Nguyen, V., Tan, P., Greenup, A., Glass, A., Davison, S., Samarasinghe, D., Holdaway, S., Strasser, S., Chatterjee, U., Jackson, K., et al (2014). Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Alimentary Pharmacology and Therapeutics, 39(10), 1225-1234. [More Information]

2004

  • Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. American Journal of Gastroenterology, 99(4), 636-644.
  • Sud, A., Hui, J., Farrell, G., Bandara, P., Kench, J., Fung, C., Lin, R., Samarasinghe, D., Liddle, C., McCaughan, G., George, J. (2004). Improved Prediction Of Fibrosis In Chronic Hepatitis C Using Measures Of Insulin Resistance In A Probability Index. Hepatology, 39(5), 1239-1247. [More Information]

2003

  • Coverdale, S., Samarasinghe, D., Lin, R., Kench, J., Byth Wilson, K., Khan, M., Crewe, E., Liddle, C., George, J., Farrell, G. (2003). Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression. American Journal of Gastroenterology, 98(6), 1384-1390.
  • Kumar, D., Wallington-Beddoe, C., George, J., Lin, R., Samarasinghe, D., Liddle, C., Farrell, G. (2003). Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hapatitis c in a clinic setting. Medical Journal of Australia, 178(6), 267-271.

2002

  • Hui, J., George, J., Liddle, C., Lin, R., Samarasinghe, D., Crewe, E., Farrell, G. (2002). Changes in Serum Albumin During Treatment of Chronic Hepatitis B With Lamivudine: Effects of Response and Emergence of Drug Resistance. American Journal of Gastroenterology, 97(4), 1003-1009.
  • Hui, J., Kench, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., Byth, K., George, J. (2002). Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., George, J., Kench, J., Byth, K. (2002). Hepatic Steatosis in Chronic Hepatitis C Infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Chitturi, S., Weltman, M., Farrell, G., McDonald, D., Liddle, C., Samarasinghe, D., Lin, R., Abeygunasekera, S., George, J. (2002). HFE Mutations, Hepatic Iron, and Fibrosis: Ethnic-Specification Association of NASH with C282Y but not with Fibrotic Severity. Hepatology, 36(1), 142-149.
  • Chitturi, S., Abeygunasekera, S., Farrell, G., Holmes-Walker, J., Hui, J., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J. (2002). NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology, 35(2), 373-379.
  • Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., George, J. (2002). Serum Leptin in NASH Correlates with Hepatic Steatosis but not Fibrosis: A Manifestation of Lipotoxicity? Hepatology, 36(2), 403-409.

2001

  • Chitturi, S., Abeygunasekera, S., Fung, C., Samarasinghe, D., Lin, R., McDonald, D., Weltman, M., Farrell, G., George, J. (2001). Haemochromatosis gene mutations, hepatic iron content and nonalcoholic steatohepatitis. Hepatology, 19, 1768-1778.
  • Farrell, G., Samarasinghe, D., Chitturi, S., Abeygunasekera, S., Fung, C. (2001). HFE mutations, hepatic iron content and nonalcoholic steatohepatitis. Journal of Gastroenterology and Hepatology, 16.
  • Coverdale, S., Samarasinghe, D., Lin, R., Liddle, C., George, J., Farrell, G., Kench, J., Byth, K., Khan, M., Crewe, E. (2001). Prediction of histological progression in chronic hepatitis C. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • George, J., Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Kench, J. (2001). Predictors for steatosis and fibrosis in chronic hepatitis C. Journal of Hepatology, 34, 153-153.
  • Farrell, G., Liddle, C., Samarasinghe, D., Chitturi, S., Frost, L. (2001). Serum is a predictor of severity of hepatic steatosis in NASH but does not correlate with fibrotic severity. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Farrell, G., Liddle, C., Samarasinghe, D., Chitturi, S., Frost, L. (2001). Serum leptin is a predictor of severity of hepatic steatosis in NASH but does not correlate with fibrotic severity. Journal of Gastroenterology and Hepatology, 16.
  • Farrell, G., Liddle, C., Samarasinghe, D., Lin, R., George, J., Chitturi, S., Frost, L. (2001). Serum Leptin: An independent predictor of hepatic steatosis but not fibrotic severity in nonalcoholic steatohepatitis. Hepatology, 34, 752-752.

To update your profile click here. For support on your academic profile contact .